小檗碱、口腔菌群、系统性疾病三者相关性的研究进展

doi:10.13591/j.cnki.kqyx.2024.10.013

Abstract

Abstract:

Berberine is a commonly used traditional Chinese medicine, which has the antimicrobial and anti-inflammatory properties. Ongoing investigations have identified berberine as an effective medicine for systemic diseases, such as cardiovascular diseases, diabetes mellitus and neurological disorders. At the same time, there exists a close relationship between oral microbiota and these systemic diseases. This review focuses on the relationship between berberine, oral microbiota and systemic diseases, offering new insights for the treatment of systemic diseases.

Key words: berberine, oral microbiota, systemic disease

CLC Number:

GUO Fanyi, WANG Ruyu, DU Yifei, WANG Yuli, ZHOU Qigang. Research progress of the relationship between berberine, oral microbiota and systemic diseases[J]. Stomatology, 2024, 44(10): 791-795.

References 52

[1]	胡茜, 张颖, 李堃, 等. 黄连主要成分小檗碱的临床药理作用探析[J]. 中国中医药现代远程教育, 2021, 19(24):203-205.
[2]	Schenkein HA, Papapanou PN, Genco R, et al. Mechanisms underlying the association between periodontitis and atherosclerotic disease[J]. Periodontol 2000, 2020, 83(1):90-106. doi: 10.1111/prd.12304 pmid: 32385879
[3]	Horliana ACRT, Chambrone L, Foz AM, et al. Dissemination of periodontal pathogens in the bloodstream after periodontal procedures: A systematic review[J]. PLoS One, 2014, 9(5):e98271.
[4]	Mylonakis E, Calderwood SB. Infective endocarditis in adults[J]. N Engl J Med, 2001, 345(18):1318-1330.
[5]	van der Meer JT, Thompson J, Valkenburg HA, et al. Epidemiology of bacterial endocarditis in The Netherlands. Ⅱ. Antecedent procedures and use of prophylaxis[J]. Arch Intern Med, 1992, 152(9):1869-1873. pmid: 1520053
[6]	Chiu B. Multiple infections in carotid atherosclerotic plaques[J]. Am Heart J, 1999, 138(5 Pt 2):S534-S536. doi: 10.1016/s0002-8703(99)70294-2 pmid: 10539867
[7]	Kurita-Ochiai T, Yamamoto M. Periodontal pathogens and atherosclerosis: Implications of inflammation and oxidative modification of LDL[J]. Biomed Res Int, 2014, 2014: 595981.
[8]	Nocini R, Favaloro EJ, Sanchis-Gomar F, et al. Periodontitis, coronary heart disease and myocardial infarction: Treat one, benefit all[J]. Blood Coagul Fibrinolysis, 2020, 31(6):339-345.
[9]	Qin XR, Zhao YF, Guo YX. Periodontal disease and myocardial infarction risk: A meta-analysis of cohort studies[J]. Am J Emerg Med, 2021, 48: 103-109. doi: 10.1016/j.ajem.2021.03.071 pmid: 33866268
[10]	Genco RJ, Graziani F, Hasturk H. Effects of periodontal disease on glycemic control, complications, and incidence of diabetes mellitus[J]. Periodontol 2000, 2020, 83(1):59-65. doi: 10.1111/prd.12271 pmid: 32385875
[11]	Matsha TE, Prince Y, Davids S, et al. Oral microbiome signatures in diabetes mellitus and periodontal disease[J]. J Dent Res, 2020, 99(6):658-665. doi: 10.1177/0022034520913818 pmid: 32298191
[12]	Hartstra AV, Bouter KEC, Bäckhed F, et al. Insights into the role of the microbiome in obesity and type 2 diabetes[J]. Diabetes Care, 2015, 38(1):159-165. doi: 10.2337/dc14-0769 pmid: 25538312
[13]	Hernandez CJ, Guss JD, Luna M, et al. Links between the microbiome and bone[J]. J Bone Miner Res, 2016, 31(9):1638-1646. doi: 10.1002/jbmr.2887 pmid: 27317164
[14]	Xiao E, Mattos M, Vieira GHA, et al. Diabetes enhances IL-17 expression and alters the oral microbiome to increase its pathogenicity[J]. Cell Host Microbe, 2017, 22(1):120-128.e4. doi: S1931-3128(17)30254-8 pmid: 28704648
[15]	Navarro-Sanchez AB, Faria-Almeida R, Bascones-Martinez A. Effect of non-surgical periodontal therapy on clinical and immunological response and glycaemic control in type 2 diabetic patients with moderate periodontitis[J]. J Clin Periodontol, 2007, 34(10):835-843. doi: 10.1111/j.1600-051X.2007.01127.x pmid: 17850602
[16]	Preshaw PM, Alba AL, Herrera D, et al. Periodontitis and diabetes: A two-way relationship[J]. Diabetologia, 2012, 55(1):21-31. doi: 10.1007/s00125-011-2342-y pmid: 22057194
[17]	Nakamura H, Jinzu H, Nagao K, et al. Plasma amino acid profiles are associated with insulin, C-peptide and adiponectin levels in type 2 diabetic patients[J]. Nutr Diabetes, 2014, 4(9):e133.
[18]	Tian J, Liu C, Zheng X, et al. Porphyromonas gingivalis induces insulin resistance by increasing BCAA levels in mice[J]. J Dent Res, 2020, 99(7):839-846. doi: 10.1177/0022034520911037 pmid: 32176550
[19]	Dominy SS, Lynch C, Ermini F, et al. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors[J]. Sci Adv, 2019, 5(1):eaau3333.
[20]	Poole S, Singhrao SK, Chukkapalli S, et al. Active invasion of Porphyromonas gingivalis and infection-induced complement activation in ApoE-/- mice brains[J]. J Alzheimers Dis, 2015, 43(1):67-80.
[21]	Liu XX, Jiao B, Liao XX, et al. Analysis of salivary microbiome in patients with Alzheimer’s disease[J]. J Alzheimers Dis, 2019, 72(2):633-640.
[22]	Adams B, Nunes JM, Page MJ, et al. Parkinson’s disease: A systemic inflammatory disease accompanied by bacterial inflammagens[J]. Front Aging Neurosci, 2019, 11: 210. doi: 10.3389/fnagi.2019.00210 pmid: 31507404
[23]	Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: Focus on astrocytes[J]. Mol Neurobiol, 2014, 49(1):28-38. doi: 10.1007/s12035-013-8483-x pmid: 23783559
[24]	Yao J, Kong WJ, Jiang JD. Learning from berberine: Treating chronic diseases through multiple targets[J]. Sci China Life Sci, 2015, 58(9):854-859. doi: 10.1007/s11427-013-4568-z pmid: 24174332
[25]	Cai Y, Xin QQ, Lu JJ, et al. A new therapeutic candidate for cardiovascular diseases: Berberine[J]. Front Pharmacol, 2021, 12: 631100.
[26]	Wan Q, Liu ZY, Yang YP, et al. Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction[J]. Int J Mol Med, 2018, 41(4):1939-1948.
[27]	Feng XJ, Sureda A, Jafari S, et al. Berberine in cardiovascular and metabolic diseases: From mechanisms to therapeutics[J]. Theranostics, 2019, 9(7):1923-1951. doi: 10.7150/thno.30787 pmid: 31037148
[28]	Li SJ, Wu CH, Chen JX, et al. An effective solution to discover synergistic drugs for anti-cerebral ischemia from traditional Chinese medicinal formulae[J]. PLoS One, 2013, 8(11):e78902.
[29]	Lan JR, Zhao YY, Dong FX, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension[J]. J Ethnopharmacol, 2015, 161: 69-81. doi: 10.1016/j.jep.2014.09.049 pmid: 25498346
[30]	Zhang H, Niu HY, Yuan XZ, et al. Trimetazidine combined with berberine on endothelial function of patients with coronary heart disease combined with primary hypertension[J]. Exp Ther Med, 2018, 16(2):1318-1322. doi: 10.3892/etm.2018.6278 pmid: 30116381
[31]	Yin J, Xing HL, Ye JP. Efficacy of berberine in patients with type 2 diabetes mellitus[J]. Metabolism, 2008, 57(5):712-717.
[32]	Chang WG, Chen L, Hatch GM. Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies[J]. Biochem Cell Biol, 2015, 93(5):479-486. doi: 10.1139/bcb-2014-0107 pmid: 25607236
[33]	Kong WJ, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins[J]. Nat Med, 2004, 10(12):1344-1351. doi: 10.1038/nm1135 pmid: 15531889
[34]	Yang J, Yin JH, Gao HF, et al. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients[J]. Evid Based Complement Alternat Med, 2012, 2012: 363845.
[35]	Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: Principles of pathogenesis and therapy[J]. Lancet, 2005, 365(9467):1333-1346. doi: 10.1016/S0140-6736(05)61032-X pmid: 15823385
[36]	Grundy SM. Drug therapy of the metabolic syndrome: Minimizing the emerging crisis in polypharmacy[J]. Nat Rev Drug Discov, 2006, 5(4):295-309. pmid: 16582875
[37]	Lane CA, Hardy J, Schott JM. Alzheimer’s disease[J]. Eur J Neurol, 2018, 25(1):59-70. doi: 10.1111/ene.13439 pmid: 28872215
[38]	Lin L, Li C, Zhang DY, et al. Synergic effects of berberine and curcumin on improving cognitive function in an Alzheimer’s disease mouse model[J]. Neurochem Res, 2020, 45(5):1130-1141. doi: 10.1007/s11064-020-02992-6 pmid: 32080784
[39]	Chen Y, Chen YL, Liang YB, et al. Berberine mitigates cognitive decline in an Alzheimer’s Disease Mouse Model by targeting both tau hyperphosphorylation and autophagic clearance[J]. Biomed Pharmacother, 2020, 121: 109670.
[40]	Ashby FG, Valentin VV, von Meer SS. Differential effects of dopamine-directed treatments on cognition[J]. Neuropsychiatr Dis Treat, 2015, 11: 1859-1875.
[41]	Wang Y, Tong Q, Ma SR, et al. Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson’s disease by regulating gut microbiota[J]. Signal Transduct Target Ther, 2021, 6(1):77.
[42]	Huang SX, Liu HQ, Lin YW, et al. Berberine protects against NLRP3 inflammasome via ameliorating autophagic impairment in MPTP-induced Parkinson’s disease model[J]. Front Pharmacol, 2021, 11: 618787.
[43]	Hu JP, Takahashi N, Yamada T. Coptidis rhizoma inhibits growth and proteases of oral bacteria[J]. Oral Dis, 2000, 6(5):297-302. doi: 10.1111/j.1601-0825.2000.tb00142.x pmid: 11002412
[44]	王希, 赖筱姮, 林菁. 奥硝唑联合小檗碱对牙周致病菌的体外抗菌活性试验[J]. 中国卫生标准管理, 2019, 10(19):95-97.
[45]	Xie Q, Johnson BR, Wenckus CS, et al. Efficacy of berberine, an antimicrobial plant alkaloid, as an endodontic irrigant against a mixed-culture biofilm in an in vitro tooth model[J]. J Endod, 2012, 38(8):1114-1117.
[46]	Tu HP, Fu MMJ, Kuo PJ, et al. Berberine’s effect on periodontal tissue degradation by matrix metalloproteinases: An in vitro and in vivo experiment[J]. Phytomedicine, 2013, 20(13):1203-1210.
[47]	Song J, Wu QS, Jiang J, et al. Berberine reduces inflammation of human dental pulp fibroblast via miR-21/KBTBD7 axis[J]. Arch Oral Biol, 2020, 110: 104630.
[48]	Zhang H, Shan Y, Wu Y, et al. Berberine suppresses LPS-induced inflammation through modulating Sirt1/NF-κB signaling pathway in RAW264.7 cells[J]. Int Immunopharmacol, 2017, 52: 93-100. doi: S1567-5769(17)30339-9 pmid: 28888780
[49]	Sun HL, Wu YR, Song FF, et al. Role of PCSK9 in the development of mouse periodontitis before and after treatment: A double-edged sword[J]. J Infect Dis, 2018, 217(4):667-680. doi: 10.1093/infdis/jix574 pmid: 29294034
[50]	Bui FQ, Almeida-da-Silva CLC, Huynh B, et al. Association between periodontal pathogens and systemic disease[J]. Biomed J, 2019, 42(1):27-35. doi: S2319-4170(18)30263-4 pmid: 30987702
[51]	Jungbauer G, Stähli A, Zhu XL, et al. Periodontal microorganisms and alzheimer disease: A causative relationship?[J]. Periodontol 2000, 2022, 89(1):59-82. doi: 10.1111/prd.12429 pmid: 35244967
[52]	Song TJ, Jeon J, Kim J. Cardiovascular risks of periodontitis and oral hygiene indicators in patients with diabetes mellitus[J]. Diabetes Metab, 2021, 47(6):101252.

Research progress of the relationship between berberine, oral microbiota and systemic diseases

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 52

Related Articles 3

Recommended Articles

Metrics

Comments

[1]	QI Linlong, QIN Zirui, TENG Jianying, ZHANG Shuyang, WANG Yuan, DENG Shuli. Application of Raman spectroscopy in the identification of oral bacteria [J]. Stomatology, 2024, 44(10): 786-790.
[2]	XIAO Jinzhi, YU Wei, ZHANG Hao. Berberine hydrochloride inhibits the proliferation of oral squamous cell carcinoma by regulating autophagy [J]. Stomatology, 2023, 43(10): 889-893.
[3]	. Study on clinical effect of berberine gel on the treatment of minor recurrent aphthous ulcer [J]. , 2017, 37(1): 61-64.